Point Biopharma Drops 28% After Phase 3 Data for a Prostate Cancer Candidate

Point Biopharma Global Inc. NASDAQ:PNT

Point Biopharma Global Inc. (NASDAQ:PNT)

After the biotech company, Point Biopharma Global Inc. (NASDAQ:PNT) announced the publication of an abstract presenting preliminary data from a Phase 3 study for its radioligand agent PNT2002, shares of the radiopharmaceutical company fell by almost 28%.

In a presentation at the next European Society for Medical Oncology (ESMO) Congress in Paris, the results from the multi-center, open-label trial’s lead-in cohort will be included.

The patients whose bodies reject chemotherapy are included in the trial are those whose illness progressed despite androgen receptor pathway inhibitor (ARPI) medication. 


Survival without radiographic progression is the trial’s main outcome. With a median rPFS follow-up of 7.5 months at the data cut-off, data from 27 patients showed that 21 (78%) of them were still free of events at nine months, with a rPFS rate of 75.4%.

11 patients (42% of the trial) had a PSA50 response, which, in Guggenheim’s opinion, can be disputed given results from prior studies and the FDA-approved drug Pluvicto from Novartis (NVS) has shown that a PSA50 response of 50% to 60% “is possible.” Point Biopharma is rated as a Buy at Guggenheim.

Researchers also noticed a fatality that was determined to be unrelated to the medication, and findings show that 8 (29.6%) of patients suffered Grade 3 treatment-emergent adverse events (TEAEs).

Relatable Case – Pluvicto

In a fairly similar case, the FDA also approved Pluvicto, a radioligand therapeutic agent, for some adults with prostate cancer in March. For its treatment of metastatic, castration-resistant, prostate cancer that is progressing and PSMA+ (PSMA+ mCRPC), pluvicto has received approval. For a total of six treatments, it is given via intravenous infusion every six weeks.

Pluvicto consists of two parts: one that binds to a particular region of the prostate cancer cell and the other that releases a dose of radiation specifically designed to kill the prostate cancer cell. The prostate-specific membrane antigen (PSMA), which is identified by a particular PET imaging scan, is a distinctive marker present in the cells of patients for whom the medication is intended.

Featured Image-  Megapixl @Prometeus

Please See Disclaimer

About the author: I'm a financial freelance writer keen on the latest market developments which i articulate with writing stock updates, press releases and investor news. As a person i live by the code of a sustainable human existence and a carbon neutral universe. When off work, i spend time reading non-fiction books, flying drones, and outdoor cycling.